Nevirapine ( DrugBank: Nevirapine )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
265脂肪萎縮症4

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00192660
(ClinicalTrials.gov)
February 200312/9/2005HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First TimeHIV-Associated Lipodystrophy Syndrome;Cardiovascular DiseaseDrug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20)Kirby InstituteSt Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/ABoth80Phase 4Australia
2NCT00122226
(ClinicalTrials.gov)
January 200314/7/2005MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)HIV Infections;HIV-Associated Lipodystrophy SyndromeDrug: Lopinavir/ritonavir + zidovudine + lamivudine;Drug: Lopinavir/ritonavir + nevirapineVU University Medical CenterAbbott;Boehringer IngelheimActive, not recruiting18 Years70 YearsMale50Phase 4Finland;Netherlands;Spain;United Kingdom
3NCT00028314
(ClinicalTrials.gov)
March 200220/12/2001Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV PatientsA Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat WastingHIV Infections;Lipodystrophy;Wasting DiseaseDrug: Abacavir sulfate;Drug: Atazanavir/Ritonavir;Drug: Lopinavir/Ritonavir;Drug: NevirapineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted13 YearsN/ABoth150N/AUnited States
4NCT00021463
(ClinicalTrials.gov)
April 200114/7/2001Changing to Nonprotease Inhibitor Treatment to Improve Side EffectsPhase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic AbnormalitiesHIV Infections;LipodystrophyDrug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: NevirapineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted13 YearsN/ABoth342Phase 2United States